Moreover, a recent study has shown that reducing ADAM17 levels has great pharmaceutical potential: reduced levels of ADAM17 in the Adam17ex/ex mouse limits colorectal cancer formation and any residual tumours are low-grade dysplasias (Schmidt et al., 2018). This evidence concerns the gene ADAM17 and neoplasm.